![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RS Chang, TB Chen, MG Bock, RM Freidinger, R Chen, A Rosegay and VJ Lotti
Department of New Lead Pharmacology, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.
[3H]L-365,260, [(3R-(+)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl)-N'-(3-methylphenyl)urea], a new potent and selective nonpeptide brain cholecystokinin (CCK-B) and gastrin receptor antagonist, bound saturably and reversibly to guinea pig brain membranes. Scatchard analysis indicated a single class of high affinity (Kd = 2.3 nM) binding sites. The binding of [3H]L-365,260 was stereospecific, because unlabeled L-365,260 (an R-enantiomer) was approximately 100 times more potent than its S-enantiomer in displacing binding. The relative potencies of various CCK/gastrin-related peptides and nonpeptide peripheral CCK-A antagonists in displacing [3H]L-365,260 brain binding correlated with their potencies in displacing the binding of 125I-CCK to brain receptors but not their potencies in displacing the peripherally selective CCK-A ligand [3H]L-364,718 from pancreatic receptors. The regional distribution of [3H]L-365,260 binding in various brain areas correlated with 125I-CCK binding. Specific [3H]L- 365,260 binding to guinea pig brain membranes was reduced by omission of NaCl but was not affected by omission of MgCl2 or addition of guanosine 5'-(beta-gamma-imido)triphosphate or various pharmacological agents known to interact with other common peptide and nonpeptide receptor systems. [3H]L-365,260 also bound in a specific manner to guinea pig gastric glands but only negligibly to guinea pig or rat pancreas. The binding of [3H]L-365,260 to gastric glands was inhibited by CCK/gastrin antagonists with potencies similar to those for inhibition of 125I-gastrin binding in this tissue. Collectively, the data indicates that [3H]L-365,260 represents a new potent nonpeptide antagonist radioligand suitable for the study of brain CCK-B and gastrin receptors.
This article has been cited by other articles:
|
|
 |
|
  T. W. Moody and R. T. Jensen CI-988 Inhibits Growth of Small Cell Lung Cancer Cells J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamazaki, W. E. Neway, T. Ohe, I-W. Chen, J. F. Rowe, J. H. Hochman, M. Chiba, and J. H. Lin In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 723 - 735. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Silvente-Poirot, C. Escrieut, C. Gales, J.-A. Fehrentz, A. Escherich, S. A. Wank, J. Martinez, L. Moroder, B. Maigret, M. Bouisson, et al. Evidence for a Direct Interaction between the Penultimate Aspartic Acid of Cholecystokinin and Histidine 207, Located in the Second Extracellular Loop of the Cholecystokinin B Receptor J. Biol. Chem., August 13, 1999; 274(33): 23191 - 23197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Glaser, R. E. D. Rodgers, J. L. Phinizy, W. E. Robertson, J. Lasater, A. Caligiuri, Z. Tretjak, G. D. Lesage, and G. Alpini Gastrin inhibits secretin-induced ductal secretion by interaction with specific receptors on rat cholangiocytes Am J Physiol Gastrointest Liver Physiol, November 1, 1997; 273(5): G1061 - G1070. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
